Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | Updates from the Munich Leukemia Lab

Torsten Haferlach • 14 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia

In this video, Torsten Haferlach, MD, from the Munich Leukemia Laboratory, Munich, Germany, talk about the latest updates in his lab. Prof. Haferlach was speaking at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Torsten Haferlach

The value of WGS and whole transcriptome sequencing in the diagnosis of hematological malignancies
3:33
The value of WGS and whole transcriptome sequencing in the diagnosis of hematological malignancies
Torsten Haferlach • 9 Dec 2023
Implementing AI in hematology and the challenges this will overcome
1:52
Implementing AI in hematology and the challenges this will overcome
Torsten Haferlach • 9 Dec 2023
Why do we need AI in the hematology clinic?
2:57
Why do we need AI in the hematology clinic?
Torsten Haferlach • 9 Dec 2023
Role of NGS in acute leukemias
1:53
Role of NGS in acute leukemias
Torsten Haferlach • 17 Sep 2020

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Torsten Haferlach • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Torsten Haferlach • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Torsten Haferlach • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Torsten Haferlach • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals